Literature DB >> 17572250

Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure.

Christine K Kissel1, Ralf Lehmann, Birgit Assmus, Alexandra Aicher, Jörg Honold, Ulrich Fischer-Rasokat, Christopher Heeschen, Ioakim Spyridopoulos, Stefanie Dimmeler, Andreas M Zeiher.   

Abstract

OBJECTIVES: This study investigated whether reduced levels of circulating endothelial progenitors cells (EPCs) in chronic heart failure (CHF) are secondary to an exhaustion of hematopoietic stem cells (HSCs) in the bone marrow or to reduced mobilization.
BACKGROUND: Circulating EPCs presumably originate from bone marrow-derived HSC. Persistent mobilization of EPCs was shown to be associated with favorable left ventricular infarct remodeling processes.
METHODS: We assessed the number and functional capacity of EPCs in 17 healthy controls, 25 patients with ischemic cardiomyopathy (ICM), and 20 patients with dilated cardiomyopathy (DCM). To document an impairment of HSC function in the bone marrow, the colony-forming unit capacity of bone marrow-derived mononuclear cells and the number of CD34+ HSCs were examined in 6 healthy volunteers, 94 ICM patients, and 25 DCM patients.
RESULTS: The number of EPCs was reduced in CHF, irrespective of its etiology. In contrast, the migratory capacity was selectively impaired in EPCs of ICM patients (4.8 +/- 4.0 migrated cells; DCM 9.7 +/- 5.8; p = 0.02). On multivariate analysis, ICM, advanced New York Heart Association functional class, and CHF were independent predictors of functional EPC impairment. The number of bone marrow-derived CD34+ cells did not differ between the CHF populations. However, colony-forming units (CFUs) were selectively reduced in ICM patients (54.4 +/- 24.6; DCM 68.1 +/- 26.9; p < 0.02). Ischemic cardiomyopathy was the only independent predictor of impaired CFU capacity. Impaired CFU capacity was associated with reduced matrix metalloproteinase-9 activity in the bone marrow plasma.
CONCLUSIONS: Ischemic cardiomyopathy is associated with selective impairment of progenitor cell function in the bone marrow and in the peripheral blood, which may contribute to an unfavorable left ventricular (LV) remodeling process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572250     DOI: 10.1016/j.jacc.2007.01.095

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  86 in total

1.  Stem cell therapy trials: a call for standardization.

Authors:  Leslie W Miller
Journal:  J Cardiovasc Transl Res       Date:  2008-07-22       Impact factor: 4.132

2.  Myocardial Regeneration by Exogenous and Endogenous Progenitor Cells.

Authors:  Annarosa Leri; Toru Hosoda; Marcello Rota; Jan Kajstura; Piero Anversa
Journal:  Drug Discov Today Dis Mech       Date:  2007

3.  Endothelial progenitor cells in adolescents: impact of overweight, age, smoking, sport and cytokines in younger age.

Authors:  Christian Jung; Nicole Fischer; Michael Fritzenwanger; Hansjörg Thude; Markus Ferrari; Marlen Fabris; Bernhard R Brehm; Dagmar Barz; Hans R Figulla
Journal:  Clin Res Cardiol       Date:  2008-11-25       Impact factor: 5.460

Review 4.  Telomeres, atherosclerosis, and the hemothelium: the longer view.

Authors:  Abraham Aviv; Daniel Levy
Journal:  Annu Rev Med       Date:  2011-10-17       Impact factor: 13.739

Review 5.  Cell therapy for the treatment of coronary heart disease: a critical appraisal.

Authors:  Kai C Wollert; Helmut Drexler
Journal:  Nat Rev Cardiol       Date:  2010-02-23       Impact factor: 32.419

6.  Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response.

Authors:  Xiaoyin Wang; Junya Takagawa; Viola C Lam; Daniel J Haddad; Diana L Tobler; Pamela Y Mok; Yan Zhang; Brian T Clifford; Kranthi Pinnamaneni; Shereen A Saini; Robert Su; Maya J Bartel; Richard E Sievers; Larry Carbone; Scott Kogan; Yerem Yeghiazarians; Michelle Hermiston; Matthew L Springer
Journal:  Sci Transl Med       Date:  2011-09-14       Impact factor: 17.956

7.  Embryonic stem cell therapy of heart failure in genetic cardiomyopathy.

Authors:  Satsuki Yamada; Timothy J Nelson; Ruben J Crespo-Diaz; Carmen Perez-Terzic; Xiao-Ke Liu; Takashi Miki; Susumu Seino; Atta Behfar; Andre Terzic
Journal:  Stem Cells       Date:  2008-07-31       Impact factor: 6.277

8.  Combination of chemokine and angiogenic factor genes and mesenchymal stem cells could enhance angiogenesis and improve cardiac function after acute myocardial infarction in rats.

Authors:  Junming Tang; Jianing Wang; Fei Zheng; Xia Kong; Linyun Guo; Jianye Yang; Lei Zhang; Yongzhang Huang
Journal:  Mol Cell Biochem       Date:  2010-01-08       Impact factor: 3.396

9.  Nutraceutical augmentation of circulating endothelial progenitor cells and hematopoietic stem cells in human subjects.

Authors:  Nina A Mikirova; James A Jackson; Ron Hunninghake; Julian Kenyon; Kyle W H Chan; Cathy A Swindlehurst; Boris Minev; Amit N Patel; Michael P Murphy; Leonard Smith; Famela Ramos; Thomas E Ichim; Neil H Riordan
Journal:  J Transl Med       Date:  2010-04-08       Impact factor: 5.531

10.  Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside.

Authors:  Ana Villegas; Fernando A Gonzalez; Leopoldo Llorente; Santiago Redondo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.